Cinclus Pharma Holding AB
Clinical-stage pharma company developing a PCAB for gastric acid-related diseases.
CINPHA | ST
Overview
Corporate Details
- ISIN(s):
- SE0020388577
- LEI:
- 549300TJBPSNZ3DO6B42
- Country:
- Sweden
- Address:
- Kungsbron 1, Plan 3, trappa G, 111 22 Stockholm
- Website:
- https://cincluspharma.com/
- Sector:
- Manufacturing
Description
Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate is linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) in late-stage clinical development. This therapeutic is being developed to treat gastroesophageal reflux disease (GERD), particularly severe erosive GERD, and for the eradication of Helicobacter pylori infections. Linaprazan glurate represents a next-generation approach, aiming to provide superior clinical efficacy and a more beneficial pharmacokinetic profile compared to traditional Proton Pump Inhibitors (PPIs). The goal is to address the unmet medical needs of patients who do not achieve sufficient disease control with current therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-30 14:00 |
Antal aktier och röster i Cinclus Pharma
|
Swedish | 84.1 KB | ||
| 2024-12-30 14:00 |
Number of shares and votes in Cinclus Pharma
|
English | 83.0 KB | ||
| 2024-12-09 08:00 |
Första dag för handel i Carasent AB (publ) på Nasdaq Stockholm
|
Swedish | 49.7 KB | ||
| 2024-12-04 15:40 |
Linaprazan glurate receives marketing approval in China
|
English | 84.6 KB | ||
| 2024-11-28 19:30 |
Emission och återköp av C-aktier
|
Swedish | 76.8 KB | ||
| 2024-11-28 19:30 |
Issue and repurchase of class C shares
|
English | 76.0 KB | ||
| 2024-11-14 08:00 | English | 2.7 MB | |||
| 2024-11-08 09:00 |
CINCLUS PHARMA’S NOMINATION COMMITTEE FOR THE 2025 ANNUAL GENERAL MEETING APPOI…
|
English | 78.7 KB | ||
| 2024-08-29 08:00 | English | 2.7 MB | |||
| 2024-07-19 18:30 |
Meddelande om stabiliseringsåtgärder, avslutande av stabiliseringsperioden och …
|
Swedish | 119.7 KB | ||
| 2024-07-11 19:00 |
Stabilization notice
|
English | 110.2 KB | ||
| 2024-07-02 14:30 | Swedish | 14.0 KB | |||
| 2024-07-01 18:30 |
Meddelande om stabiliseringsåtgärder
|
Swedish | 109.9 KB | ||
| 2024-06-28 08:45 |
Antal aktier och röster i Cinclus Pharma
|
Swedish | 80.6 KB | ||
| 2024-06-20 07:30 |
Första dag för handel i Cinclus Pharmas stamaktier på Nasdaq Stockholm
|
Swedish | 114.6 KB |
Automate Your Workflow. Get a real-time feed of all Cinclus Pharma Holding AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cinclus Pharma Holding AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cinclus Pharma Holding AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
